This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bishop, P. C. Articles by Elwood, P. C. Search for Related Content PubMed PubMed Citation Articles by Bishop, P. C. Articles by Elwood, P. C. Social Bookmarking                            What's this?

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

From the Division of Clinical Science, Medicine Branch, National Cancer Institute, Bethesda, MD.

Address reprint requests to Patrick C. Elwood, MD, National Cancer Institute, 9000 Rockville Pike, Bldg 10/12N226, Bethesda, MD 20892.

PURPOSE: The risk of CNS involvement by non-Hodgkin's Lymphoma (NHL) has been associated with bone marrow and/or testicular involvement; however, it was recently reported that the number of extranodal sites is a more reliable predictor of CNS disease. Because primary mediastinal thymic large B-cell lymphoma (PMLCL) has a high propensity for involving extranodal sites, we investigated the frequency and pattern of CNS involvement in PMLCL.

PATIENTS AND METHODS: The medical records of 219 patients with aggressive NHL, consecutively entered onto protocols at the National Cancer Institute between 1987 and 1998, were retrospectively reviewed.

RESULTS: Twenty-three patients (11%) had clinical and pathologic features of PMLCL. These patients were young (median age, 29 years), female (61%), and presented with massive mediastinal adenopathy (70%). Extranodal disease occurred at presentation in 70% and at relapse in 93% of patients and involved contiguous intrathoracic structures and/or distant sites, including the lungs, kidneys, liver, adrenals, ovaries, pancreas, and bone. Six patients (26%) developed CNS involvement, two (9%) at presentation and four (27%) at relapse. All had extranodal disease, but only one had bone marrow involvement. Parenchymal and leptomeningeal CNS disease occurred in four and three patients, respectively.

CONCLUSION: CNS involvement in PMLCL is associated with extranodal involvement other than bone marrow and may reflect the unique biology of this disease. The propensity to involve the CNS parenchyma raises the concern that intrathecal prophylaxis may not be effective and suggests that CNS imaging should be considered in patients with extranodal disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Quijano, A. Lopez, J. Manuel Sancho, C. Panizo, G. Deben, C. Castilla, J. Antonio Garcia-Vela, A. Salar, N. Alonso-Vence, E. Gonzalez-Barca, et al. Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry J. Clin. Oncol., March 20, 2009; 27(9): 1462 - 1469. [Abstract] [Full Text] [PDF]

				A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutierrez, S. Mercadal, E. Campo, C. Rozman, A. Lopez-Guillermo, et al. Central nervous system involvement in mantle cell lymphoma Ann. Onc., January 1, 2008; 19(1): 135 - 141. [Abstract] [Full Text] [PDF]

				P. W.M. Johnson and A. J. Davies Primary Mediastinal B-Cell Lymphoma Hematology, January 1, 2008; 2008(1): 349 - 358. [Abstract] [Full Text] [PDF]

				H-T Arkenau, G Chong, D Cunningham, D Watkins, R Agarwal, B Sirohi, M Trumper, A Norman, A Wotherspoon, and A Horwich The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma Ann. Onc., March 1, 2007; 18(3): 541 - 545. [Abstract] [Full Text] [PDF]

				A. Rosenwald, G. Wright, K. Leroy, X. Yu, P. Gaulard, R. D. Gascoyne, W. C. Chan, T. Zhao, C. Haioun, T. C. Greiner, et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma J. Exp. Med., September 15, 2003; 198(6): 851 - 862. [Abstract] [Full Text] [PDF]

				R. F. Little, S. Pittaluga, N. Grant, S. M. Steinberg, M. F. Kavlick, H. Mitsuya, G. Franchini, M. Gutierrez, M. Raffeld, E. S. Jaffe, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology Blood, June 15, 2003; 101(12): 4653 - 4659. [Abstract] [Full Text] [PDF]

				K. Seidemann, M. Tiemann, I. Lauterbach, G. Mann, I. Simonitsch, K. Stankewitz, M. Schrappe, M. Zimmermann, C. Niemeyer, R. Parwaresch, et al. Primary Mediastinal Large B-Cell Lymphoma With Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-Munster Group J. Clin. Oncol., May 1, 2003; 21(9): 1782 - 1789. [Abstract] [Full Text] [PDF]

				W. H. Wilson, M. L. Grossbard, S. Pittaluga, D. Cole, D. Pearson, N. Drbohlav, S. M. Steinberg, R. F. Little, J. Janik, M. Gutierrez, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy Blood, April 15, 2002; 99(8): 2685 - 2693. [Abstract] [Full Text] [PDF]

				K. van Besien, M. Kelta, and P. Bahaguna Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management J. Clin. Oncol., March 15, 2001; 19(6): 1855 - 1864. [Abstract] [Full Text] [PDF]